Our Mission

Biobide’s aim is to accelerate R&D process for Pharma, Biotech, Chemical, Cosmetic and Nutraceutical companies minimizing risks through our zebrafish services, adding value to clients R&D&i mainly in preclinical area.

We are a CRO specialized in zebrafish working under Good Laboratory Practice (GLP) and thanks to our automated and innovative tools, we have developed and validated time and cost effective Toxicity and Efficacy Assays, as well as disease models to be used in preclinical stages.

The followed strategy is based on:

1
Excellent services:

to develop, in an environment of Good Laboratory Practice, reliable and relevant assays for our Customers, Regulatory Bodies and, ultimately, for Human Health based on an experimental design and interpretation of results supported by a first-rate technology platform and innovative tools.

2
Expert team:

to integrate into our processes the capabilities required to understand and apply advances in genetic and physiological research, automation, image analysis and all other areas of knowledge which impact on our business model.

3
Global business:

having a network of alliances and strategic partnerships to develop and launch together new solutions to the market.

4
Recognition:

to achieve our Customers and Regulatory bodies being the promoters of our services.

Our History

Biobide was founded in 2005 in order to resolve the main problem that contemporary biotechnological and pharmaceutical companies were facing: how to deal with the low success rate in marketing new drugs and block busters. In 2014, the company was acquired by the Bionaturis Group. During 2018, Bionaturis acquired ADL Biopharma by a reverse acquisition.

The Newco after the integration, ADL Bionatur Solutions is a biotech European leader focused in R&D and manufacturing high value fermentation products for human and animal health. ADL Bionatur Solutions is quoted on the alternative Spanish stock exchange for SME (MaB, ticker ADL).

Biobide's Organization Chart

Victor Infante
President and CEO

Mr. Infante holds PhD in Science and Chemical degree. Appointed CEO and President of Bionaturis since 2005 and Managing Director of BNT Pacific Limited, and Chairman of Biobide Board of Directors.

Andoni Cruz Pacheco
Co-founder and General Manager

Besides Biobide, Mr. Cruz is also co-founder of several ongoing companies, such as Imatec Innovación, GTCluster and Cyberclick. Mr. Cruz is Member of the Board of Biobide.

Arantza Muriana Miralles
Co-founder and R+D Management Director

Mrs. Muriana has the bachelor of Pharmacy and Master degree in R+D+i of New Drugs at the University of Navarra. In addition, she has a MBA from the San Pablo CEU University of Madrid and she is Member of the Board of Biobide.

Ainhoa Alzualde Zuloaga
Study Director

Ainhoa completed her PhD. in Physical Anthropology, Animal Physiology and Genetics. She is responsible of projects related to behavioral assays, ecotoxicity tests and organ specific toxicities as cardiotoxicity or muscle toxicity among others.

Celia Quevedo Soubriet
Study Director

Celia took a PhD. in Biochemistry and Molecular Biology after studying the regulation of protein initiation factors in neurons. She manages different projects related with development of models, as well as some general and organ specific toxicities such as teratogenicity or ototoxicity.